Abstract. Fifteen 
Abstract. Fifteen premenopausal women were investigated in the follicular phase of the menstrual cycle with two TRH tests within an interval of 48 to 96 h. Ninety min before each TRH test either 10 mg metoclopramide or saline was injected iv in randomized order. The same procedure was repeated in the following menstrual cycle after pretreatment with T4 (0.5 mg daily for [6] [7] [8] [9] [10] [11] [12] [13] [14] 
days).
At least 2 months later the same procedure was repeated with T3 pretreatment (60-120 \g=m\g for [6] [7] [8] (1, 2, 3) . The role of estrogen is still a matter of controversy, but administration of oral contraceptives increases both basal (4) and TRH-stimulated TSH release (5) . The (6) , indicating a mechanism inde¬ pendent of the thyroid hormone level. In animals (7) and in man (8, 9) TSH was 0.1-4.0 mIU/1 and the detection limit was 0.03 mIU/1. The intra-assay coefficients of variation (CV) at low, medium and high levels for serum TSH were 4.1,5.8 and 1.6%, and the inter-assay 2.8, 2.5 and 6.2%, respec¬ tively. Serum free T4 and T3 were measured in duplicate by RIA (Amersham International, Amersham, UK). The intra-assay CVs for serum free T4 at normal, high and very high levels were 3.0, 7.5, and 4.1%, and the interassay 5.1, 5.8, and 6.7%, respectively. For serum free T3 the intra-assay CVs for the corresponding levels were 2.5, 4.5, and 2.5%, and the inter-assay 3.9, 3.5, and 3.5%, respectively. The reference interval for serum free T3 was 2.9-8.9 pmol/1, and for serum free T4 10-25 pmol/1. Serum estradiol was measured by radioimmunoassay (12) with intra-and inter-assay CVs of less than 14%. The reference interval for women in the early follicular phase was 90-180 pmol/1, and in the preovulatory phase 700-1500 pmol/1. Serum SHBG was measured by radioimmu¬ noassay (13) During treatment with T4 or T3, the TSH re¬ sponse to TRH was lower than in the control situ¬ ation but not fiat (Fig. 2) . Also when the subjects were on T3 or T4 treatment the TSH response at the second TRH test was reduced, by 69% (p<0.001). In parallel with the control situation this blunting was less pronounced after metoclopra¬ mide. When metoclopramide had been given 90 min prior to the second TRH test the TSH incre¬ mental area was reduced by 57.9±5.2% (±sd), whereas the corresponding figure for tests pre¬ ceded by saline was 72.6±4.4% (p<0.05).
PRL was assayed in blood samples taken simul¬ taneously with those used for TSH assay. A stepwise multiple regression analysis showed that the PRL response to the second administration of TRH was not influenced by the first one (11) .
Discussion
The decline in serum TSH after saline during the 90 min preceding the administration of TRH was of the same degree as that observed by others during the morning hours and interpreted as the settling of the nocturnal elevation of TSH secretion (14) that reaches a nadir around 11.00 h (15) . Thus, GnRH administration did not seem to affect the serum TSH level, which is in accordance with the absence of a GnRH effect on TSH secretion alone (16) , or in combination with TRH (17) (18) (19) .
Metoclopramide blocks D2 receptors on prolactin cells (20) and in the mesostriatal area of the hypothalamus (21) . As administered in the present investigation it increases serum PRL within 5 min and keeps it elevated for at least 2 hours (22) . Fur¬ ther, there is a linear relationship between the plasma concentrations of metoclopramide and of PRL (23) . Metoclopramide prevented the decrease in serum TSH between 0 and 90 min in our sub¬ jects. This effect is in agreement with earlier ob¬ servations (24, 25) and seems to be more pro¬ nounced in hypothyroidism (26) . However, we found no general effect of metoclopramide on TRH-stimulated TSH release, neither at normal nor at elevated serum levels of thyroid hormones. This is in accordance with earlier investigations in euthyroid women (27) as well as in hyperthyroid subjects (28, 29) . In euthyroid men the results have been contradictory (24, 30) . Thus, the present re¬ sults confirm the presence of a dopaminergic inhi¬ bition of TSH secretion in man.
Estrogen stimulates anterior pituitary cells di¬ rectly (31) and enhances pituitary TRH binding sites (32) , and exogeneous estradiol augments the TSH response to TRH (5, 33, 34) . However, basal serum TSH (4) has not been found to vary with the normal menstrual cycle, and for TRH-stimulated TSH the reports are contradictory (35, 36 (6, 37) , and at 4-h intervals when given iv (38) . The blunting has generally been ascribed to a concomitant in¬ crease in serum T3 and T4, and is assumed to be more pronounced after oral than iv administration of TRH, as serum TSH remains elevated longer (1, 37) and the T3 and T4 levels were higher in the former case (37, 39 (42) where these transmitters are impor¬ tant for the main inhibitory and facilitating mech¬ anisms in the regulation of TSH secretion (7, 43 
